Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre
| Autor: | R. J. Benjamin, Walter Nussbaumer, C. Y. Chen, M. Amato, Harald Schennach, M. Astl, Jin-Sying Lin |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Blood Platelets Male medicine.medical_specialty Time Factors Adolescent Ultraviolet Rays Patient risk Blood Component Transfusion Platelet Transfusion 030204 cardiovascular system & hematology Gastroenterology Cohort Studies 03 medical and health sciences Patient safety Young Adult 0302 clinical medicine Internal medicine Furocoumarins medicine Humans Platelet Adverse effect Child Pathogen inactivation Aged Aged 80 and over business.industry Blood component Infant Hematology General Medicine Middle Aged Hospitals Cardiac surgery Surgery Austria Child Preschool Virus Inactivation Female business Erythrocyte Transfusion 030215 immunology Uva light |
| Zdroj: | Vox sanguinis. 112(1) |
| ISSN: | 1423-0410 |
| Popis: | Background In clinical studies, pathogen inactivation (PI) of platelet concentrates (PC) with amotosalen and UVA light did not impact patient risk for haemorrhage but may affect transfusion frequency and component utilization. We evaluated the influence of platelet PI on PC, red cell concentrate (RCC) and plasma use and safety in routine practice in a large regional hospital. Study Design and Methods Comparative effectiveness of conventional vs. PI-treated PC was analysed during two 21-month periods, before and after PI implementation. Results Similar numbers of patients were transfused in the pre-PI (control, 1797) and post-PI (test, 1694) periods with comparable numbers of PC (8611 and 7705, respectively). The mean numbers of PC per patient transfused (4·8 vs. 4·5, P = 0·43) were not different but days of PC support (5·9 vs. 5·0, P < 0·01) decreased. Most patients received RCC (86·8% control vs. 84·8% test, P = 0·90) with similar mean numbers transfused (10·8 vs. 10·2 RCC, P = 0·22), and fewer patients (55·4% control vs. 44·7% test, P < 0·01) received less plasma units (mean 9·9 vs. 7·8, respectively, P < 0·01) in the test period. The frequencies of transfusion-related adverse events (AE) were comparable (1·3% vs. 1·4%, P = 0·95). Analysis of haematology–oncology (522 control, 452 test), cardiac surgery (739 control, 711 test), paediatric (157 control, 130 test) and neonate (23 control, 20 test) patients revealed no increase in PC, plasma and RCC utilization, or AE. Conclusion Component utilization and patient safety were not impacted by adoption of PI for PC. RCC use per patient was comparable, suggestive of no increase in significant bleeding. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text